Antibody Profiling for HTLV-I-Associated Myelopathy
Author Information
Author(s): Burbelo Peter D, Meoli Elise, Leahy Hannah P, Graham Jhanelle, Yao Karen, Oh Unsong, Janik John E, Mahieux Renaud, Kashanchi Fatah, Iadarola Michael J, Jacobson Steven
Primary Institution: National Institute of Dental and Craniofacial Research
Hypothesis
Can antibody responses to HTLV-I proteins help differentiate between asymptomatic carriers and patients with HAM/TSP or ATLL?
Conclusion
Anti-HTLV-I antibody responses detected by LIPS are useful for diagnosis, with elevated anti-Env antibodies being a common feature in HAM/TSP patients.
Supporting Evidence
- Anti-GAG antibody titers differentiated HTLV-infected subjects from uninfected controls with 100% sensitivity and specificity.
- Anti-Env antibody titers were over 4-fold higher in HAM/TSP compared to asymptomatic HTLV-I carriers.
- Anti-Tax antibody titers were also higher in HAM/TSP compared to asymptomatic HTLV-I carriers.
Takeaway
This study found that certain antibodies can help doctors tell if someone has a specific illness related to a virus called HTLV-I.
Methodology
The study used luciferase immunoprecipitation technology (LIPS) to profile antibody responses to seven HTLV-I proteins in various patient groups.
Potential Biases
Potential biases in participant selection and the interpretation of antibody responses could affect the results.
Limitations
The study may not account for all demographic variations and the antibody responses may not be universally applicable across different populations.
Participant Demographics
{"gender":{"male":61.9,"female":38.1},"race":{"white":47.6,"african_descent":23.8,"hispanic":7.1},"mean_age":44}
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 3.7–33.5
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website